AVTX (Avalo Therapeutics) Cash per Share: $3.33 (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Avalo Therapeutics Inc AVTX

23 GF Score

Price $19.01

GF Value $0.03

Valuation Significantly Overvalued

5 Warning Signs

View Full Analysis

What is Avalo Therapeutics Cash per Share?

Avalo Therapeutics AVTX -2.61% 23 Cash per Share is $3.33 as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Avalo Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 was $3.33.

Avalo Therapeutics (NAS:AVTX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Avalo Therapeutics Cash per Share Related Terms

Avalo Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Cash per Share Chart

Avalo Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

1,399.62

337.74

9.25

12.85

5.31

Avalo Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															11.55	10.45	6.26	5.31	3.33

23GF Score

Avalo Therapeutics Inc AVTX

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Avalo Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Avalo Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	98.336	/	18.51
	=	5.31

Avalo Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	81.993	/	24.64
	=	3.33

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $3.33 mean?

Avalo Therapeutics (AVTX) has a Cash per Share of $3.33 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Avalo Therapeutics and its competitors.

Is Avalo Therapeutics' Cash per Share too high?

Avalo Therapeutics' current Cash per Share is $3.33. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Avalo Therapeutics' Cash per Share compare to MRVI and LBRX?

Avalo Therapeutics' Cash per Share of $3.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Avalo Therapeutics and its competitors. Avalo Therapeutics's current Cash per Share is $3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Avalo Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $19.01 — trading 63266.7% above its estimated fair value. The current Cash per Share is $3.33. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Cash per Share is $3.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $19.01 is trading 63266.7% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

Cash per Share: $3.33
GF Value™: $0.03 vs. price of $19.01 (63266.7% above fair value)
GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies MRVI LBRX JANX LXRX EYPT OLMA KURA PHAT GERN ANRO VRTX REGN XBRU:ARGX XBRU:UCB XKRX:207940 RVMD ASX:CSL ALNY ONC XKRX:068270

Other Exchanges C6K0:Germany

Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087

Website https://www.avalotx.com

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

23GF Score

Get the complete analysis for AVTX

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.01

Price

$0.03

GF Value

View AVTX Analysis

See Cash per Share data for all stocks →